pd 169316 has been researched along with Multiple Myeloma in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitsiades, N | 1 |
| Mitsiades, CS | 1 |
| Poulaki, V | 1 |
| Chauhan, D | 1 |
| Richardson, PG | 1 |
| Hideshima, T | 1 |
| Munshi, N | 1 |
| Treon, SP | 1 |
| Anderson, KC | 1 |
1 other study available for pd 169316 and Multiple Myeloma
| Article | Year |
|---|---|
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Topics: Apoptosis; Caspases; Cell Nucleus; Cell Survival; Cytochrome c Group; Enzyme Inhibitors; Humans; Imi | 2002 |